National Psoriasis Foundation

 

National Psoriasis Foundation Amgen Medical Dermatology Fellowships

Ten residents and medical students each received a one-year, $50,000 National Psoriasis Foundation fellowship to study psoriasis and psoriatic arthritis. The National Psoriasis Foundation Amgen Medical Dermatology Fellowships aims to increase the number of scientists studying and treating psoriatic diseases by encouraging promising doctors to dedicate their careers to psoriasis and psoriatic arthritis as physician researchers.

The fellowships connect an early-career doctor with an established psoriatic disease researcher who will oversee their work.

The 2014 fellows are:

  • Zelma Chiesa Fuxench, M.D., of the University Of Pennsylvania Perelman School Of Medicine, will determine risks of major cardiovascular events in people with psoriasis and whether treating with the drug Humira (adalimumab) improves vascular inflammation. She will also study the effect of certain psoriasis treatments on skin cancer risk.

  • Jessica Donigan, M.D., M.P.H., of Massachusetts General Hospital/Harvard Medical School, will evaluate why psoriasis plaques appear to be more stigmatizing than the lesions from other dermatologic diseases. 

  • Rivka Friedland, M.D., of Northwestern University, will examine the safety and efficacy of systemic medications and phototherapy on psoriasis in children. 

  • Dario Kivelivetch, M.D., of Baylor Research Institute, will evaluate cardiovascular risk in people with psoriasis using coronary artery calcium scores, which are special X-ray tests that can check for early-stage heart disease to determine its severity. 

  • Davida Kornreich, M.D., of the Icahn School of Medicine at Mt. Sinai, will analyze whether applying topicals in different orders changes their effectiveness. Kornreich will also study the safety and effectiveness of a holistic treatment in moderate to severe plaque psoriasis.

  • Marina Li, B.S., a third-year medical student at Case Western Reserve University, will examine whether reducing skin inflammation also reduces blood clots and other signs of cardiovascular disease. 

  • Forum Patel, M.D., of the University of California, Davis, will identify if complex sugars called glycans are biomarkers, or biological signs, of psoriasis.

  • Scott Santilli, M.D., of University Hospital Case Medical Center, will examine the effect of systemic, or whole-body, psoriasis therapy and its potential to regulate cardiovascular risk in people with psoriasis. 

  • Aimee Two, M.D., of University of California, San Diego, will investigate the role of dendritic cells, or pro-inflammatory cells in the immune system, in psoriasis and whether hyaluronidase, an enzyme that may cause dendritic cells to move away from the skin, may be effective at stopping inflammation.

  • Shaowei Wu, M.D., Ph.D., of Brown University, will use data from two on-going national Nurses’ Health Studies to investigate the relationship between pregnancy, menstruation, menopause and postmenopausal hormone use in the risk of psoriatic disease. 

 The fellowships are supported by a grant from Amgen.

National Psoriasis Foundation Our Mission: To drive efforts to cure psoriatic disease and improve the lives of those affected.